Art. -Nr.: HY-B0202

Irbesartan

(Synonyms: SR-47436; BMS-186295)

8 Cited Publications

Kundenbewertung

Based on 8 publication(s) in Google Scholar

Irbesartan (SR-47436) is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan can be used for the research of high blood pressure, heart failure, and diabetic kidney disease.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.95%
CAS. Nr.: 138402-11-6
Formel: C₂₅H₂₈N₆O
Molecular Weight:428.53

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Irbesartan Chemical Structure

CAS. Nr.: 138402-11-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (8)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Angiotensin Receptor Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
HASMC	IC₅₀	0.32 μM Compound: SR-47436	Inhibitory activity against Ang II-induced proliferation of human aortic smooth muscle cells in a dose-dependent manner Inhibitory activity against Ang II-induced proliferation of human aortic smooth muscle cells in a dose-dependent manner	[PMID: 8576904]
HEK293	IC₅₀	>500 μM Compound: irbesartan	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
PLC-PRF-5	IC₅₀	3 nM Compound: Irbesartan	In vitro antagonist activity, Inhibition of angiotensin II (50 nM) mediated increase in cytosolic [Ca2+] conc. in PLC-PRF-5 cells In vitro antagonist activity, Inhibition of angiotensin II (50 nM) mediated increase in cytosolic [Ca2+] conc. in PLC-PRF-5 cells	[PMID: 10893306]

In Vitro

Irbesartan (20 μM, 3 h) reduces Th22 cells chemotaxis in vitro^[1].
Irbesartan (0 μM, 20 μM, 40 μM and 60 μM) suppresses Th22 cells differentiation in vitro^[1].
Irbesartan (20 μM) inhibits Th22 cells related proinflammatory response of TECs in vitro^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

CD4+ T cells
Concentration:

0, 20, 40 and 60 μM
Incubation Time:

48 h
Result:

Exerted no obvious effect on viability of CD4⁺T cells.

In Vivo

Irbesartan (oral gavage; 50 mg/kg/d; once daily) reduces Th22 lymphocytosis and serum IL-22 level in Ang II-infused mice^[1].
Irbesartan (oral gavage; 50 mg/kg/d; once daily) exerts obvious renoprotective effects^[1].
Irbesartan (oral gavage; 50 mg/kg/d; once daily) relieves systemic inflammation and renal fibrosis in hypertension mice induced by Ang II^[1].
Irbesartan hydrochloride (20 μM; for 3 h) can attenuate Th22 cells recruitment and IL-22 secretion, which might be through inhibiting chemotaxis in hypertensive renal injury mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 mice^[1]
Dosage:

50 mg/kg
Administration:

oral gavage; 50 mg/kg/d; once daily
Result:

Displayed low Th22 cells and IL-22, exerted similar inhibitory effect on Th1 cell proportion and displayed decreased IL-22 level in kidney.
Prevented BP elevation markedly and decreased urinary albumin/creatinine ratio, BUN and Scr.
Repressed the expression of IL-1β, IL-6, TNF-α, α-SMA, FN and Col I and diminished the extent of fibrosis.

Animal Model:

C57BL/6 mice^[1]
Dosage:

20 μM
Administration:

20 μM; for 3 h
Result:

Downregulated renal CCL20, CCL22 and CCL27 concentrations.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 138402-11-6
Appearance Solid
Molecular Weight 428.53
Formel C₂₅H₂₈N₆O
Color White to off-white
SMILES

O=C1N(CC2=CC=C(C3=C(C4=NN=NN4)C=CC=C3)C=C2)C(CCCC)=NC15CCCC5
Synonyms

SR-47436; BMS-186295
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (8)

All WBCell Imaging/StainingIn Vivo Efficacy StudyIF

Sort by:

Journal Impact Factor

J Exp Clin Cancer Res

Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis. [Abstract]

2023 May 4;42(1):111. PMID: 37143164

Irbesartan purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2023 May 4;42(1):111. [Abstract]

The apoptosis of organoids treated with GEM (0.8 μM) and Irbesartan (1 μM) for 72 h was determined by western blot for cleaved-caspase 3/7. Tubulin was used as loading control.

Irbesartan purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2023 May 4;42(1):111. [Abstract]

Organoids were treated with vehicle, GEM (0.8 μM), irbesartan (1 μM) and GEM (0.8 μM) plus irbesartan (1 μM), followed by continually monitoring PDAC organoid apoptosis by real-time caspase3/7 probe imaging for 72 h.

Irbesartan purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2023 May 4;42(1):111. [Abstract]

Irbesartan (20 mg/kg; po; twice a week) plus GEM significantly reduced the weight of pancreatic tumor.

Irbesartan purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2023 May 4;42(1):111. [Abstract]

Irbesartan (20 mg/kg; po; twice a week) induced apoptosis in mouse pancreatic tumor tissues.

Irbesartan purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2023 May 4;42(1):111. [Abstract]

Irbesartan (20 mg/kg; po; twice a week) decreased the percent of Ki67 positive cells in mouse pancreatic tumor tissues.
J Immunother Cancer

Telmisartan increases olaparib efficacy in homologous recombination proficient tumors by augmenting type I interferon production. [Abstract]

2026 Mar 25;14(3):e012426. PMID: 41881499
Int J Biol Macromol

An injectable polyacrylamide/chitosan-based hydrogel with highly adhesive, stretchable and electroconductive properties loaded with irbesartan for treatment of myocardial ischemia-reperfusion injury. [Abstract]

2024 May;266(Pt 1):131175. PMID: 38552696
Phytother Res

Saikosaponin D Regulates HK2-Mediated Glycolytic Lactate Signaling to Alleviate CKD-Induced Renal Fibrosis. [Abstract]

2026 Feb;40(2):812-828. PMID: 41508401
Atherosclerosis

RhoGDI stability is regulated by SUMOylation and ubiquitination via the AT1 receptor and participates in Ang II-induced smooth muscle proliferation and vascular remodeling. [Abstract]

2019 Sep:288:124-136. PMID: 31362179
FASEB J

Hirudin Ameliorates Kidney Injury in DKD Mice by Decreasing SOD2 β-Hydroxybutyrylation Mediated ROS Level and NLRP3 Inflammasome Formation. [Abstract]

2026 Jan 31;40(2):e71433. PMID: 41546551
Biomedicines

Comparative Proteomic Analysis of tPVAT during Ang II Infusion. [Abstract]

2021 Dec 2;9(12):1820. PMID: 34944635
Saudi Pharm J

Study of influence of Catha edulis (Khat) chewing on oral pharmacokinetics of irbesartan in rats using a newly developed HPLC-UV method. [Abstract]

2022 Mar;30(3):237-244. PMID: 35498225

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (233.36 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3336 mL

11.6678 mL

23.3356 mL

5 mM

0.4667 mL

2.3336 mL

4.6671 mL

10 mM

0.2334 mL

1.1668 mL

2.3336 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.83 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.83 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.83 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Schupp M, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation. 2004 May 4;109(17):2054-7. Epub 2004 Apr 26. [Content Brief]

[2]. Ruiz E, et al. Importance of intracellular angiotensin II in vascular smooth muscle cell apoptosis: inhibition by the angiotensin AT1 receptor antagonist irbesartan. Eur J Pharmacol. 2007 Jul 19;567(3):231-9. Epub 2007 Apr 6. [Content Brief]

[3]. Yong Zhong, et al. Irbesartan may relieve renal injury by suppressing Th22 cells chemotaxis and infiltration in Ang II-induced hypertension. Int Immunopharmacol [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3336 mL	11.6678 mL	23.3356 mL	58.3390 mL
	5 mM	0.4667 mL	2.3336 mL	4.6671 mL	11.6678 mL
	10 mM	0.2334 mL	1.1668 mL	2.3336 mL	5.8339 mL
	15 mM	0.1556 mL	0.7779 mL	1.5557 mL	3.8893 mL
	20 mM	0.1167 mL	0.5834 mL	1.1668 mL	2.9169 mL
	25 mM	0.0933 mL	0.4667 mL	0.9334 mL	2.3336 mL
	30 mM	0.0778 mL	0.3889 mL	0.7779 mL	1.9446 mL
	40 mM	0.0583 mL	0.2917 mL	0.5834 mL	1.4585 mL
	50 mM	0.0467 mL	0.2334 mL	0.4667 mL	1.1668 mL
	60 mM	0.0389 mL	0.1945 mL	0.3889 mL	0.9723 mL
	80 mM	0.0292 mL	0.1458 mL	0.2917 mL	0.7292 mL
	100 mM	0.0233 mL	0.1167 mL	0.2334 mL	0.5834 mL

Irbesartan

8 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Irbesartan

Anti-Infection Compound Library

Apoptosis Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Anti-diabetic Compound Library

Anti-Cardiovascular Disease Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

Neurotransmitter Receptor Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Angiogenesis-Related Compound Library

Rare Diseases Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Off-patent Drug Library

Antihypertensive Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Nephrotoxicity Compound Library

Lactylation Compound Library

Classic FDA-Approved Drug Library

Publications Citing Use of MedChemExpress (MCE) Irbesartan

Alle Angiotensin Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (8)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Irbesartan Related Classifications

HY-B0202 Related Classifications